Mindblown: a blog about philosophy.
-
From Famine to Fortune: Jullian Kyoshabire Launches JK Collective To Inspire a New Movement in Wellness, Wealth and Legacy
Through The Live Well Method, entrepreneur, author and technology professional Jullian Kyoshabire is bringing wellness, education, innovation and community together to help individuals and families live well, build well and leave a lasting legacy. Dallas-Fort Worth, TX, USA – November 10, 2026 – What if building a healthier life could become the foundation for building…
-
Christian D. Evans Steps Into Mar-a-Lago as CPAC Co-Host and Unleashes New Book on Power and Greatness
LFG America Chairman and Pax Fortis Family Office CEO connects discipline, personal responsibility, and character-driven leadership with a gathering focused on conservative strategy, human dignity, and the future of the CPAC movement. Palm Beach, FL, USA – November 10, 2026 – Christian D. Evans, chairman of LFG America and chief executive officer of Pax Fortis…
-
US Solar Energy Market CAGR to rise upto 10.96% by 2031, Driven by Solar-Plus-Storage Projects and Residential Installations, Says Mordor Intelligence
US Solar Energy Industry The latest research by Mordor Intelligence covers the “US Solar Energy Market” delivering insights into market dynamics, drivers of growth, and long-term forecasts. Hyderabad, India – November 10, 2026: The US solar energy market is projected to increase from 269.54 GW in 2026 to 453.37 GW by 2031, registering a CAGR…
-
Influenza Pipeline Insights 2026: Novel Mechanisms, Promising Candidates, and Competitive Landscape by DelveInsight | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Cidara
(Albany, New York) – November 10, 2026: As per DelveInsight’s assessment, globally, Influenza pipeline constitutes 120+ key companies continuously working towards developing 120+ Influenza treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. “Influenza Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present…
-
Atrial Fibrillation Clinical Trials Update 2026: Phase-Wise Pipeline Status, Drug Profiles, and Key Developers by DelveInsight | Bayer, Johnson and Johnson, Bristol Myers Squibb, Daiichi Sankyo,Pfizer
(Albany, New York) – November 10, 2026: As per DelveInsight’s assessment, globally, Atrial Fibrillation pipeline constitutes 12+ key companies continuously working towards developing 15+ Atrial Fibrillation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. “Atrial Fibrillation Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights…
-
Huntington’s Disease Pipeline 2026: Who Is Leading the Race? Top Companies and Emerging Therapies to Watch by DelveInsight | Spark therapeutics, Chong Kun Dang Pharma, Neuvivo, UniQure Biopharma
(Albany, New York) – November 10, 2026: As per DelveInsight’s assessment, globally, Huntington’s Disease pipeline constitutes 20+ key companies continuously working towards developing 20+ Huntington’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Huntington’s Disease Pipeline report embraces in-depth commercial and clinical assessment…
-
Soft Tissue Sarcoma Pipeline Landscape 2026: Late-Stage Candidates, MOA Trends, and ROA by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings
(Albany, New York) – November 10, 2026: As per DelveInsight’s assessment, globally, Soft Tissue Sarcoma pipeline constitutes 70+ key companies continuously working towards developing 75+ Soft Tissue Sarcoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. “Soft Tissue Sarcoma Pipeline Insight, 2026“ report by DelveInsight…
-
Age-related Macular Degeneration Clinical Trial Pipeline Expands as 90+ Companies Race to Redefine AMD Treatment Landscape | DelveInsight
The Age-related Macular Degeneration clinical trial analysis report delivers important insights into ongoing research on 100+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) November 10, 2026 – DelveInsight’s “Age-Related Macular Degeneration Pipeline Insight 2026” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in the Age-Related Macular Degeneration pipeline…
-
Respiratory Syncytial Virus Market Anticipated to Witness Remarkable Growth by 2034, Says Latest Industry Analysis | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharma
The Key Respiratory Syncytial Virus Companies in the market include – GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Ark Biosciences, Bavarian Nordic, ModernaTX, Inc.,…
-
Chronic Myeloid Leukemia Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The Chronic Myeloid Leukemia market analysis report delivers important insights into ongoing research on pipeline Chronic Myeloid Leukemia drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On November 10, 2026, DelveInsight’s “Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2036” report provides comprehensive insights into the Chronic Myeloid Leukemia (CML) market…
Got any book recommendations?